Total synthesis of L, L-isodityrosine and isodityrosine-derived agents: K-13, OF4949-III, and OF4949-IV
DL Boger, D Yohannes
Index: Boger, Dale L.; Yohannes, Daniel Journal of Organic Chemistry, 1990 , vol. 55, # 24 p. 6000 - 6017
Full Text: HTML
Citation Number: 81
Abstract
Full details of the development of reaction conditions for implementation of an activated Ullmann condensation reaction that may be conducted without amino acid racemization and that have proven suitable for incorporation of the selectively protected catechol of functionalized L-Dopa derivatives are described. The application of this procedure in the total synthesis of L, L-iscdityrosine (15), K-13 (I), and OF4949-III/OF4949-IV (4/5) is ...
Related Articles:
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads
[Huang, Yifang; Strobel, Eric D.; Ho, Chih Y.; Reynolds, Charles H.; Conway, Kelly A.; Piesvaux, Jennifer A.; Brenneman, Douglas E.; Yohrling, George J.; Moore Arnold; Rosenthal, Daniel; Alexander, Richard S.; Tounge, Brett A.; Mercken, Marc; Vandermeeren, Marc; Parker, Michael H.; Reitz, Allen B.; Baxter, Ellen W. Bioorganic and Medicinal Chemistry Letters, 2010 , vol. 20, # 10 p. 3158 - 3160]
Development of tripeptidyl farnesyltransferase inhibitors
[Lee, Hee-Yoon; Sohn, Jeong-Hun; Kwon, Byoung-Mog Bioorganic and medicinal chemistry letters, 2002 , vol. 12, # 12 p. 1599 - 1602]
[Acikalin, Serdar; Raabe, Gerhard; Runsink, Jan; Gais, Hans-Joachim European Journal of Organic Chemistry, 2011 , # 30 p. 5991 - 6008]
Development of tripeptidyl farnesyltransferase inhibitors
[Bioorganic and medicinal chemistry letters, , vol. 12, # 12 p. 1599 - 1602]
Development of tripeptidyl farnesyltransferase inhibitors
[Bioorganic and medicinal chemistry letters, , vol. 12, # 12 p. 1599 - 1602]